IN THE MATTER OF * BEFORE THE
DELSY LIMA, PHARM TECH * STATE BOARD
Registration No.: T18334 * OF
Respondent * PHARMACY
* Case No. PT-17-023

ORDER FOR SUMMARY SUSPENSION

Pursuant to Md. Code Ann., State Gov’t II (SG II) §10-226 (c) (2)
(2014 Repl. Vol.), the State Board of Pharmacy (the "Board") hereby suspends the
registration to practice as a Pharmacy Technician (Pharm Tech) in Maryland issued to
DELSY LIMA, (the "Respondent"), under the Maryland Pharmacy Act (the "Act"), Md.
This Order is based on the following investigative findings, which the Board has reason
to believe are true:

INVESTIGATIVE FINDINGS¹

1. At all times relevant hereto, the Respondent was registered to practice as
a Pharm Tech in Maryland. The Respondent was first registered on July 22, 2016. The
Respondent’s registration expires on April 30, 2018.

2. At all times relevant hereto, the Respondent was employed as a Pharm
Tech at a National chain pharmacy in Hyattsville, Prince George’s County, Maryland,
hereinafter the "Pharmacy." ²

¹ The allegations set forth in this Notice are intended to provide the Respondent with notice of the Board’s
action. They are not intended as, and do not necessarily represent, a complete description of the
evidence, either documentary or testimonial, to be offered against the Respondent in connection with this
Notice.
Alprazolam, 0.5 mg 28 tablets;
Alprazolam, 1 mg 76 tablets;
Alprazolam, 1 XR\(^5\) mg 5 tablets;
Alprazolam, 2 mg 300 tablets;
Lorazepam\(^6\), 0.5 mg 558 tablets;
Lorazepam, 1 mg 787 tablets;
Lorazepam, 2 mg 33 tablets.

**CONCLUSIONS OF LAW**

Based on the foregoing, the Board finds that the public health, safety or welfare imperatively requires emergency action, pursuant to SG II §10-226 (c) (2).

**ORDER**

Based on the foregoing, it is therefore this 17\(^{th}\) day of July, 2017, by a majority vote of a quorum of the State Board of Pharmacy, by authority granted to the Board by SG II §10-226 (c) (2), the registration held by the Respondent to practice as a Pharm Tech in Maryland, Registration No. T18334, is hereby **SUMMARILY SUSPENDED**; and be it further

ORDERED that, upon the Board's receipt of a written request from the Respondent, a Show Cause Hearing shall be scheduled within a reasonable time of said request, at which the Respondent will be given an opportunity to be heard as to

---

\(^5\) XR stands for extended release.

\(^6\) Lorazepam belongs to a group of drugs called benzodiazepines. It affects chemicals in the brain that may be unbalanced in people with anxiety. Lorazepam is used to treat anxiety disorders.
whether the Respondent is fit to practice as a Pharm Tech and/or a danger to the
public, and whether the Summary Suspension should be continued; and be it further

ORDERED, that the Respondent shall immediately turn over to the Board her
wall certificate and wallet-sized registration to practice as a Pharm Tech issued by the
Board; and be it further

ORDERED that this document constitutes a final Order of the Board and is,
therefore, a public document for purposes of public disclosure, as required by Md.

Deena Speights-Napata, Executive Director
Board of Pharmacy

NOTICE OF HEARING

A Show Cause hearing to determine whether the Summary Suspension shall be
continued will be held before the Board at 4201 Patterson Avenue, Baltimore, 21215
following a written request by the Respondent for same.